肿瘤标志物在肺癌诊断、预后预测中的临床价值

Clinical value of tumor markers in diagnosis and prognosis of lung cancer patients

目的分析肿瘤标志物在肺癌诊断及预后预测中的临床应用价值。方法选取肺癌患者68例为观察者,同期参与体检且结果健康者72例为对照组,检测两组血清肿瘤标志物。结果观察组糖类抗原(CA) 125、CA153、癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、细胞角蛋白19片段(CYFRA21-1)水平均明显高于对照组(P<0. 05),小细胞肺癌组CA125、CA153、CEA、NSE、CYFRA21-1阳性率显著高于对照组(P<0. 05);肺鳞癌与肺腺癌组CA125、CA153、CEA、CYFRA21-1阳性率显著高于对照组(P<0. 05),肺鳞癌组CA125、CYFRA21-1阳性率显著高于小细胞肺癌组(P<0. 05),肺腺癌组CA125、CA153、CEA阳性率显著高于小细胞肺癌组(P<0. 05),肺腺癌组CA125、CA153、CEA、CYFRA21-1阳性率与肺鳞癌组比较差异显著(P<0. 05)。统计3年死亡情况,死亡患者中肿瘤标志物阳性率明显高于存活患者(P<0. 05),死亡患者两项及以上肿瘤标志物阳性率明显多于存活患者(P<0. 05)。结论肿瘤标志物可为肺癌患者的诊断及预后预测提供重要信息。

Objective To analyze the clinical value of tumor markers in the diagnosis and prognosis of lung cancer patients.Methods 68 patients with lung cancer were selected as observers.72 patients who participated in the physical examination and healthy results were selected as the control group.The serum tumor markers were detected and compared.Results The levels of CA125,CA153,CEA,NSE and CYFRA21-1 in the observation group were significantly higher than those in the control group(P<0.05).The positive rates of tumor markers in lung cancer patients with different pathological types were different.The 3-year mortality was analyzed.The number of positive tumor markers in the dead patients was significantly higher than that in the surviving patients(P<0.05).Conclusions Tumor markers could provide important information for the diagnosis and prognosis of lung cancer patients.